Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (111-120 of 283) with videos related to

Pageof 29
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 31, 2016
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell TransplantIbraheem H Motabi, Armin Ghobadi, Jingxia Liu, et al.
Investigational New Drugs|May 24, 2013
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)Pankaj Gupta, Flora Mulkey, Robert P Hasserjian, et al.
British Journal of Haematology|August 1, 2012
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibRavi Vij, David S Siegel, Sundar Jagannath, et al.
British Journal of Haematology|January 11, 2014
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistanceFeda Azab, Shireen Vali, Joseph Abraham, et al.
Blood|November 6, 2010
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemiaTodd A Fehniger, Geoffrey L Uy, Kathryn Trinkaus, et al.
Blood|May 6, 2004
Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamideMark Girgis, Chris Hallemeier, William Blum, et al.
Transplantation and Cellular Therapy|May 22, 2022
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related MortalityLawrence Wayne Liu, Alicia Yn, Feng Gao, et al.
Leukemia & Lymphoma|April 29, 2016
A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndromeMathew A Cherian, Raoul Tibes, Feng Gao, et al.
Leukemia & Lymphoma|February 1, 2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myelomaJeffrey L Wolf, David Siegel, Hartmut Goldschmidt, et al.
Cancers|February 5, 2020
Targeting CD47 as a Novel Immunotherapy for Multiple MyelomaJennifer Sun, Barbara Muz, Kinan Alhallak, et al.
Pageof 29

Showing results (111-120 of 283) with videos related to

Sort By:
Pageof 29
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 31, 2016
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell TransplantIbraheem H Motabi, Armin Ghobadi, Jingxia Liu, et al.
Investigational New Drugs|May 24, 2013
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)Pankaj Gupta, Flora Mulkey, Robert P Hasserjian, et al.
British Journal of Haematology|August 1, 2012
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibRavi Vij, David S Siegel, Sundar Jagannath, et al.
British Journal of Haematology|January 11, 2014
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistanceFeda Azab, Shireen Vali, Joseph Abraham, et al.
Blood|November 6, 2010
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemiaTodd A Fehniger, Geoffrey L Uy, Kathryn Trinkaus, et al.
Blood|May 6, 2004
Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamideMark Girgis, Chris Hallemeier, William Blum, et al.
Transplantation and Cellular Therapy|May 22, 2022
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related MortalityLawrence Wayne Liu, Alicia Yn, Feng Gao, et al.
Leukemia & Lymphoma|April 29, 2016
A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndromeMathew A Cherian, Raoul Tibes, Feng Gao, et al.
Leukemia & Lymphoma|February 1, 2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myelomaJeffrey L Wolf, David Siegel, Hartmut Goldschmidt, et al.
Cancers|February 5, 2020
Targeting CD47 as a Novel Immunotherapy for Multiple MyelomaJennifer Sun, Barbara Muz, Kinan Alhallak, et al.
Pageof 29